“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."
Largest contemporary randomized trial demonstrates benefit following myocardial infarction in patients with preserved or mildly reduced ejection fraction.